ROBERT JAMIESON: Open Payments
NPI 1184602757 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,370 in 94 payments from 9 companies in 2025. Trend: 2023 $9,240 · 2024 $1,572 · 2025 $1,370
Food & beverage: $1,370
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 60 | $741 |
| Teva Pharmaceuticals USA, Inc. | 8 | $175 |
| E.R. Squibb & Sons, L.L.C. | 16 | $174 |
| restor3d, inc. | 1 | $98 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| ABBVIE INC. | 1 | $26 |
| HARMONY BIOSCIENCES LLC | 1 | $20 |
| Alkermes, Inc. | 1 | $14 |
Products named: INGREZZA, COBENFY, AUSTEDO XR, REXULTI, CAPLYTA, VRAYLAR, WAKIX, UZEDY.
Industry payments across TN — which companies pay providers there.
